Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer
NCT00036556
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
941
Enrollment
INDUSTRY
Sponsor class
Conditions
Prostatic Neoplasms
Interventions
DRUG:
Atrasentan
Sponsor
Abbott